J80 A41
Conditions
Interventions
Group 1: Within the scope of this study the following parameters will be measured of 30 patients with severe ARDS at the time points onset, 5d and 10d: general laboratory parameters (e.g. number of le
Sponsors
Universitätsklinikum Heidelberg
Eligibility
Sex/Gender
All
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Patients with severe ARDS: *Written consent form of study participant or his appointed representative *Age > 18 years *ARDS-criteria have to be fulfilled (Berlin definition 2012) Healthy-probands: *Written consent form of study participant or his appointed representative *Age > 18 years *no acute or chronical inflammatory disease
Exclusion criteria
Exclusion criteria: *Non-fulfillment of inclusion criteria *Chronic inflammatory disease *immune suppressive therapy *pregnancy *HIV positive patients *Refusal of participation in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| *Detection of the inflammatory induced cytocine-production, as well as the oxidative- and carbonyl-stress in Plasma and BAL samples of ARDS patients at the timepoints: onset, 5d and 10d. | — |
Secondary
| Measure | Time frame |
|---|---|
| *Evaluation of the individual patients outcome according to the MG-concentration in plasma and BAL samples of ARDS patients at the timepoints: onset, 5d and 10d. *Pulmonary microbiome analyse and its changes during the therapy at the timepoints(BAL): onset, 5d and 10d. | — |
Countries
Germany
Contacts
Public ContactFelix Carl Fabian Schmitt
Universitätsklinikum HeidelbergKlinik für Anästhesiologie
Outcome results
None listed